• Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.26
+0 (0.00%)
Get New Conformis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CFMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CFMS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Conformis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.26.

This chart shows the closing price for CFMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Conformis. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
11/11/2022OppenheimerBoost TargetOutperform$1.25 ➝ $8.00Low
8/11/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$50.00 ➝ $25.00Low
11/4/2021OppenheimerLower TargetOutperform$62.50 ➝ $50.00High
9/22/2021OppenheimerLower TargetOutperform$75.00 ➝ $62.50Low
11/8/2020CowenReiterated RatingOutperform$50.00Medium
8/6/2020OppenheimerInitiated CoverageBuy$75.00High
6/24/2020CowenReiterated RatingOutperform$50.00High
5/12/2020BTIG ResearchReiterated RatingHoldHigh
5/12/2020OppenheimerLower TargetOutperform$87.50 ➝ $75.00High
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
5/2/2019OppenheimerSet TargetBuy$100.00High
5/2/2019BTIG ResearchReiterated RatingBuy$75.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Conformis logo
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $2.26
Low: $2.25
High: $2.27

50 Day Range

MA: $2.25
Low: $2.22
High: $2.26

52 Week Range

Now: $2.26
Low: $1.05
High: $7.25

Volume

7,000 shs

Average Volume

99,585 shs

Market Capitalization

$17.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Conformis?

The following Wall Street sell-side analysts have issued research reports on Conformis in the last year: Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for CFMS.

What is the current price target for Conformis?

0 Wall Street analysts have set twelve-month price targets for Conformis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Conformis in the next year.
View the latest price targets for CFMS.

What is the current consensus analyst rating for Conformis?

Conformis currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CFMS, but not buy more shares or sell existing shares.
View the latest ratings for CFMS.

What other companies compete with Conformis?

How do I contact Conformis' investor relations team?

Conformis' physical mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier's listed phone number is (781) 345-9001 and its investor relations email address is [email protected]. The official website for Conformis is www.conformis.com. Learn More about contacing Conformis investor relations.